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Summary
Beta-haemolytic streptococci of groups C and G have be-
come increasingly recognized as causes of invasive hu-
man infections. We reviewed clinical and molecular char-
acteristics of Streptococcus dysgalactiae isolates that
caused bacteraemia in adults from 2006 to 2015. Among
67 episodes, skin and soft-tissue infections (43%) and
emm types stG62647.0 (26%) were the most frequent clin-
ical manifestation and emm type, respectively. Nineteen
(28%) episodes occurred in intravenous drug users (75%
women). Our observational study shows similarities to but
also differences from other reports. The former include
the most frequent clinical presentations, and the most fre-
quently found emm types. This report highlights a relative-
ly high proportion of female intravenous drug users among
S. dysgalactiae bacteraemia episodes.
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tococcus, group C Streptococcus
Introduction
Beta-haemolytic streptococci of groups C and G (GCS
and GGS) have become increasingly recognized as causes
of invasive human infections [1–3]. The vast majority of
GGS and GCS belong to Streptococcus dysgalactiae, of
which subsp. equisimilis dominate. They cause a spectrum
of disease similar to that of Streptococcus pyogenes. Pre-
vious publications reported that the most common clinical
manifestations of S. dysgalactiae infections include skin
and soft-tissue infections, followed by bacteraemia of un-
known origin. These infections are often observed in elder-
ly patients and those with underlying medical conditions
[1–6]. Here, we investigate the demographics, comorbidi-
ties, clinical manifestations of patients who experienced S.
dysgalactiae bacteraemia and presented to our centre (Bern
University Hospital, Bern, Switzerland). In addition, the
distribution of S. dysgalactiae emm types was determined.
Methods
Blood culture isolates from 1 January 2006 to 31 Decem-
ber 2015 were identified retrospectively through database
searches in the laboratory of the Institute for Infectious
Diseases of University of Bern, Switzerland. Available iso-
lates were thawed from the bacterial collection stored at
˗80°C. The bacteria were identified with use of Ultraflex-
treme MALDI-TOF mass spectrometry (Bruker Daltonics,
Bremen, Germany), using the MALDI Biotyper version
3.0 with the BDAL-5627 Database. A score ≥2.0 was re-
quired for species determination. To determine the Lance-
field antigen, latex agglutination (Remel Europe Ltd.,
Dartford, UK) was performed. Upon identification of S.
dysgalactiae bacteraemia episodes, patient charts were re-
viewed to obtain clinical information for each episode.
The episodes were categorised in single episode, multiple
episodes (different emm type in each episode) and relaps-
ing episodes (identical emm type in each episode). Bac-
teraemia that reoccurred within <1 month after the first
episodes were designated to the same episode.
DNA emm type determination was performed as described
previously [7]. All available isolates were subjected to
emm typing as described (http://www.cdc.gov/streplab).
Statistical analyses were performed using the Prism 6 soft-
ware. Differences in group proportions were assessed by
use of contingency tables and the chi-square test, or Fish-
er’s exact probability test if a frequency was smaller than
5. A two-tailed p-value of ≤0.05 was considered signifi-
cant. The study was approved by the local ethics commit-
tee (2016-01614).
Results
Sixty-seven GCS and GGS isolates causing bacteraemia
in 61 patients were identified in the database. Six patients
had two episodes. Two isolates were not available for emm
type determination. Thus, the denominators for frequency
analyses were 67 episodes, 61 patients and 65 isolates
(table 1 and fig. 1a). Sixty-one of them were categorised
as single episodes, five as multiple episodes (different emm
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type in two episodes) and one as relapsing episode (identi-
cal emm type in both episodes). The demographics, distri-
bution of gender and comorbidities are presented in table
1. The most frequent clinical manifestations were skin
and soft-tissue infections, followed by bacteraemia without
identified source and septic arthritis. These three entities
represented 82% of the clinical manifestations. Sixteen
(26%) patients with 19 (28%) episodes were intravenous
drug users (IVDUs). Twelve (75%) of them were women.
The difference in proportion of women between IVDUs
and non-IVDUs was significant (p = 0.0003 with chi-
square test).
Six (9.8%) patients had a second episode that occurred be-
tween 41 to 269 days after the first episode. Three of them
were IVDUs.
StG62647.0 was the most frequent emm type (26.2%), fol-
lowed by stG245.0 (10.8%) and stG485.0 (10.8%) (fig.
1a). All but one isolate with emm type stG62647.0 were
designated to GCS. No emm type was significantly associ-
ated with a clinical manifestation, but there was a trend as-
sociation between the most frequent clinical manifestation
(skin- and soft-tissue disease) and most frequent emm type
(stG62647.0) (p = 0.07 with chi-square test).
In five of the six patients with two episodes, emm types
were different in both episodes. This observation included
three female IVDUs with 67, 210 and 269 days interval be-
tween the two episodes of bacteraemia. In one patient, the
GCS bacteraemia reoccurred after 41 days, and both iso-
lates were emm type stG62647.0. The source of relapsing
bacteraemia was not found in a patient with a kidney trans-
plant, despite extensive investigations.
The analyses of emm types among IVDUs did not show
patterns of an outbreak (fig. 1b). Eleven different emm
types caused 18 episodes (one isolate was not available for
analyses).
Discussion
Our observational study shows similarities to but also dif-
ferences from other reports. As in other publications [1–6],
the most frequent clinical manifestations were skin and
soft-tissue infections, bacteraemia without identified
source and septic arthritis (table 1). Recurrence rate of S.
dysgalactiae bacteraemia of up to 10% have been report-
ed [8, 9]. In these cases, the second episode occurs typi-
cally ≥1 month after the first one [10]. In our series, six
patients (9.8%) had a second episode of bacteraemia, but
recurrence with the same emm type was observed in only
one patient. Similar to our previous investigation on recur-
rent S. dysgalactiae bacteraemia [10], we did not identi-
fy comorbidity risk factors for a second episode of S. dys-
galactiae bacteraemia.
Previous publications have highlighted that invasive S.
dysgalactiae infection typically occurs in elderly patients
with comorbidities [1–6, 11]. This was also the case in
our series. However, we were surprised that 16 (26%) of
61 patients were IVDUs. Broyles et al. [4] reported that
6% (12 out of 212) of patients with invasive S. dysgalac-
tiae infection in the Atlanta metropolitan area (Georgia,
USA) and San Francisco Bay metropolitan area (Califor-
nia, USA) were IVDUs. In the 1990s, associations of IV-
DU and beta-haemolytic streptococcal bacteraemia were
reported with group A Streptococcus (GAS) [12, 13]. Sim-
ilarly, epidemics and endemic disease caused by GAS was
reported in IVDUs in our geographic area (Bern, Switzer-
land) in 2001 [14]. Interestingly, several studies have ob-
served that the overall incidence of invasive GCS and
Figure 1: (a) Pie-chart with proportional distribution of 65 emm types of Streptococcus dysagalactiae isolates causing bacteraemia in adults
over a 10-year period. Each colour represents one emm type. Two isolates were not available for emm type determination (na). One isolate
was not typable (nt). (b) Distribution of emm types of S. dysgalactiae isolates causing 19 episodes of bacteraemia in 16 patients with intra-
venous drug use. Each square represents an episode, each colour a specific emm type. One isolate was not available for emm type analysis
(na, grey colour). The date of bacteraemia is indicated within each square. In three female patients two episodes of bacteraemia with 67 days
interval (4 Oct and 10 Dec 2008), 210 days interval (29 May and 26 Dec 2008), and 269 days interval (6 Oct 2009 and 02 Jul 2010), respec-
tively, occurred. In 2012, four episodes in four patients (three women, one man) with two emm types was noted.
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GGS infections has increased significantly in the last two
decades (Norway [6], Denmark [15], Canada [16], Aus-
tralia [17]). Because of our study design, we cannot ex-
plain the reason for the relatively high proportion of IVDU
patients in our series. It is possible that the aforementioned
epidemiological trend of infections due to GCS and GGS
affected this risk group, also.
The female predominance within the IVDU group was also
surprising and raised the speculation of an outbreak possi-
bly transmitted via needle sharing or intimate contact.
From emm typing and temporal distribution, however, we
did not see patterns of an outbreak (fig. 1b). Transmission
between individuals may have happened (e.g., episodes in
2012, fig. 1b), though whole genome sequencing was not
performed in the two potential episodes.
The results of molecular analyses are in line with that of
others [7, 10]. StG62647.0 was the most frequent emm type
and all but one of them were designated to GCS [7, 10, 18].
The trend association of skin and soft-tissue disease and
Table 1: Patient characteristics and comorbid conditions in adult pa-
tients with Streptococcus dysgalactiae bacteraemia.
Characteristics 61 patients*
Demographics in 61 patients
Median age (range) in years 57.0 (2–88)
Women, n (%) 23 (62.3)
Bacteriology in 67 episodes
Group C Streptococcus, n (%) 22 (32.8)
Group G Streptococcus, n (%) 45 (67.2)
Polymicrobial bacteraemia, n (%) 18 (26.9)
Comorbid conditions of 61 patients
Arterial hypertension, n (%) 26 (42.6)
Congestive heart failure, n (%) 18 (29.5)
Diabetes mellitus, n (%) 17 (27.9)
Impairment of renal function†, n (%) 16 (26.2)
Intravenous drug abuse, n (%) 16 (26.2)
Active or history of malignancy, n (%) 15 (24.6)
Alcohol abuse, n (%) 8 (13.1)
Chronic pulmonary disease‡, n (%) 7 (11.5)
Peripheral arterial occlusive disease, n (%) 6 (9.8)
Solid organ transplants, n (%) 3 (4.9)
Clinical manifestations in 67 episodes
Skin- and soft-tissue infections, n (%) 29 (43.3)
Erysipelas, n 17
Cellulitis, n 3
Necrotising fasciitis, n 1
Skin and/or soft tissue abscess 6
Infected foot ulcer, n 2
Bacteraemia without identified source*, n (%) 17 (25.4)
Septic arthritis, n (%) 9 (13.4)
Infective endocarditis, n (%) 3 (4.5)
Neutropenic colitis, n (%) 3 (4.5)
Other clinical manifestations, n (%) 6 (8.9)
Bacterial peritonitis, n 2
Spinal epidural abscess, n 1
Vascular graft infection, n 1
Puerperal sepsis, n 1
Osteomyelitis, n 1
* Six patients had two episodes. † Impairment of renal function was
defined when glomerular filtration rate was <60ml/min. ‡ Chronic pul-
monary disease included chronic obstructive pulmonary disease,
bronchial asthma and interstitial lung disease. The number of comor-
bidities and the corresponding proportion is bigger than the number of
patients and 100%, respectively, because some patients had several
comorbidities.
stG62647.0 may be a co-incidence of the most frequent
clinical manifestation and the most frequent emm type. To-
gether with the results from our previous studies [7, 10],
we found no significant indication that a specific S. dys-
galactiae emm type is predominately found in a specific
clinical manifestation.
Our study has limitations, including its retrospective nature
and the use of medical records for data collection. Given
the microbiological focus of our study, we could not
analyse detailed data on the clinical course of the disease.
Follow-up examinations to investigate possible transmis-
sion between IVDU patients were not possible because we
were unable to contact these patients. Finally, the absolute
number of isolates was relatively low, making statistically
solid interpretation difficult.
In conclusion, our single-centre observation of S. dys-
galactiae bacteraemia confirms clinical and molecular re-
sults from other centres, but also highlights a relatively
high proportion of female IVUDs among the analysed S.
dysgalactiae bacteraemia episodes. Possible routes of
transmission include needle transmission or intimate con-
tact with colonised individuals. A prospective and qualita-
tive study is needed to investigate the transmission of GCS
and GGS, and to confirm the relatively high frequency of
IVDUs among patients with S. dysgalactiae bacteraemia.
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